by Barry101 | Nov 15, 2022 | Press Release, Uncategorized
– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Cash position expected to fund operations through end of 2023 OCALA, Fla., Nov. 15, 2022 — AIM ImmunoTech Inc....
by Barry101 | Nov 14, 2022 | Press Release, Uncategorized
– Data selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting – Treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic)...
by Barry101 | Nov 9, 2022 | Press Release, Uncategorized
Board Plans to Initiate Process to Add Two Additional Directors with Focus on Diverse Candidates who Possess Biotechnology Commercialization Experience Compensation Committee to Engage Nationally Recognized Independent Compensation Consultant to Evaluate Current...
by Barry101 | Nov 3, 2022 | Press Release, Uncategorized
OCALA, Fla. – AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that shareholders have re-elected all three of the Company’s directors, Stewart L. Appelrouth, Thomas K. Equels and William M. Mitchell,...
by Barry101 | Nov 2, 2022 | Press Release, Uncategorized
Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity currently being evaluated for the treatment of globally important cancers, viral diseases and disorders of the immune system Ampligen has demonstrated positive results for the treatment...
by Barry101 | Oct 31, 2022 | Press Release, Uncategorized
Court Denies Jonathan Jorgl’s Request for Preliminary Injunction; Finds that Jorgl Failed to Show Director Nomination Notice Complied with AIM’s Bylaws and that Evidence Suggests Notice was Misleading Activist Group Cannot Nominate Directors to AIM’s...
